FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308395721> ?p ?o ?g. }

• W4308395721 abstract "<h3>Background</h3> With standard therapy, which includes chemotherapy and aggressive surgical debulking, relative 5-year survival for newly diagnosed advanced epithelial ovarian cancer is only 30%. AV-OVA-1 is a personal vaccine consisting of autologous dendritic cells (DC) loaded ex vivo with autologous tumor antigens (ATA) from a lysate of irradiated cells from a short-term cell culture. After completion of primary chemotherapy, immunization with DC-ATA may improve survival. A multi-center, 2:1 double-blind randomized phase 2 clinical trial was designed to compare treatment with AV-OVA-1 to autologous monocytes (MC). One objective was to determine the feasibility of collecting fresh ovary cancer and establishing cell cultures to serve as the ATA source. <h3>Methods</h3> Tumor samples were obtained during surgical debulking of patients with stage 3 or 4 ovary epithelial cancer. Fresh tumor was placed in media and shipped via transport kit per overnight courier to AIVITA where a cell suspension was placed into culture and incubated in serum-free medium with factors that favor survival and proliferation of stem cells and early progenitor cells, i.e, tumor initiating cells (TICS). The objective was to harvest a minimum of 1 million cells within 28 days, and preferably 10 million cells or more. <h3>Results</h3> Patients were enrolled from five sites in California and one in Colorado. Tumors were collected between December 2017 and April 2021. 92 patients consented for tumor collection, but 12 were not malignant ovary, 4 withdrew consent, 3 had insufficient tissue to send, 1 had wrong stage; so, 72 malignant epithelial ovary tumors were placed into culture. 70/72 (97.2%) resulted in a successful cell culture; one could not be grown, one was contaminated. Of tumors submitted for patients who were subsequently randomized, 47/56 (84%) were in culture for 28 days or less, 4 (7%) were in culture for 29 to 35 days, and the remaining 5 were cultured 51, 52, 57, 62, and 67 days. All 56 cultures yielded at least 1 million cells; 48/56 (86%) yielded more than 10 million cells. The average number of irradiated cells per culture was 59.7 million (range 1.1 to 135 million); the median was 65.6 million (interquartile range 22.4 to 96.8 million). <h3>Conclusions</h3> Self-renewing ovary TIC cultures were reliably and rapidly established for use as the antigen source for personal DC-ATA vaccines. <h3>Trial Registration</h3> Clinicaltrials. gov NCT00331526 <h3>Ethics Approval</h3> This study was approved by the Western IRB, approval number 20171661; all participants gave written informed consent before taking part." @default.
• W4308395721 created "2022-11-11" @default.
• W4308395721 creator A5002245039 @default.
• W4308395721 creator A5013377891 @default.
• W4308395721 creator A5019932237 @default.
• W4308395721 creator A5031268602 @default.
• W4308395721 creator A5038366642 @default.
• W4308395721 creator A5040451836 @default.
• W4308395721 creator A5060087252 @default.
• W4308395721 creator A5068446974 @default.
• W4308395721 creator A5071014149 @default.
• W4308395721 creator A5088320829 @default.
• W4308395721 date "2022-11-01" @default.
• W4308395721 modified "2023-09-25" @default.
• W4308395721 title "562 Tumor collection and establishment of tumor-initiating cell cultures to serve as the antigen source for AV-OVA-1 dendritic cell vaccines for patients with newly diagnosed advanced ovarian cancer" @default.
• W4308395721 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0562" @default.
• W4308395721 hasPublicationYear "2022" @default.
• W4308395721 type Work @default.
• W4308395721 citedByCount "0" @default.
• W4308395721 crossrefType "proceedings-article" @default.
• W4308395721 hasAuthorship W4308395721A5002245039 @default.
• W4308395721 hasAuthorship W4308395721A5013377891 @default.
• W4308395721 hasAuthorship W4308395721A5019932237 @default.
• W4308395721 hasAuthorship W4308395721A5031268602 @default.
• W4308395721 hasAuthorship W4308395721A5038366642 @default.
• W4308395721 hasAuthorship W4308395721A5040451836 @default.
• W4308395721 hasAuthorship W4308395721A5060087252 @default.
• W4308395721 hasAuthorship W4308395721A5068446974 @default.
• W4308395721 hasAuthorship W4308395721A5071014149 @default.
• W4308395721 hasAuthorship W4308395721A5088320829 @default.
• W4308395721 hasBestOaLocation W43083957211 @default.
• W4308395721 hasConcept C121608353 @default.
• W4308395721 hasConcept C126322002 @default.
• W4308395721 hasConcept C143998085 @default.
• W4308395721 hasConcept C147483822 @default.
• W4308395721 hasConcept C203014093 @default.
• W4308395721 hasConcept C2776662205 @default.
• W4308395721 hasConcept C2776694085 @default.
• W4308395721 hasConcept C2777701055 @default.
• W4308395721 hasConcept C2778324911 @default.
• W4308395721 hasConcept C2780427987 @default.
• W4308395721 hasConcept C2781100745 @default.
• W4308395721 hasConcept C2908973413 @default.
• W4308395721 hasConcept C502942594 @default.
• W4308395721 hasConcept C71924100 @default.
• W4308395721 hasConceptScore W4308395721C121608353 @default.
• W4308395721 hasConceptScore W4308395721C126322002 @default.
• W4308395721 hasConceptScore W4308395721C143998085 @default.
• W4308395721 hasConceptScore W4308395721C147483822 @default.
• W4308395721 hasConceptScore W4308395721C203014093 @default.
• W4308395721 hasConceptScore W4308395721C2776662205 @default.
• W4308395721 hasConceptScore W4308395721C2776694085 @default.
• W4308395721 hasConceptScore W4308395721C2777701055 @default.
• W4308395721 hasConceptScore W4308395721C2778324911 @default.
• W4308395721 hasConceptScore W4308395721C2780427987 @default.
• W4308395721 hasConceptScore W4308395721C2781100745 @default.
• W4308395721 hasConceptScore W4308395721C2908973413 @default.
• W4308395721 hasConceptScore W4308395721C502942594 @default.
• W4308395721 hasConceptScore W4308395721C71924100 @default.
• W4308395721 hasLocation W43083957211 @default.
• W4308395721 hasOpenAccess W4308395721 @default.
• W4308395721 hasPrimaryLocation W43083957211 @default.
• W4308395721 hasRelatedWork W2065800215 @default.
• W4308395721 hasRelatedWork W2133480631 @default.
• W4308395721 hasRelatedWork W2417777390 @default.
• W4308395721 hasRelatedWork W2441220653 @default.
• W4308395721 hasRelatedWork W2623286990 @default.
• W4308395721 hasRelatedWork W2993962813 @default.
• W4308395721 hasRelatedWork W3097676887 @default.
• W4308395721 hasRelatedWork W4362706485 @default.
• W4308395721 hasRelatedWork W59268075 @default.
• W4308395721 hasRelatedWork W988078783 @default.
• W4308395721 isParatext "false" @default.
• W4308395721 isRetracted "false" @default.
• W4308395721 workType "article" @default.